These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 870000)

  • 61. [Hereditary dysfibrinogenaemia. Study of a family (author's transl)].
    Voinnesson A; Salaün M
    Sem Hop; 1979 Oct 8-15; 55(33-34):1507-12. PubMed ID: 229560
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [The transformation fibrinogen-fibrin in umbilical cord blood. A contribution to fetal fibrinogen].
    Krause WH; Maus W
    Med Welt; 1975 Nov; 26(48):2172-4. PubMed ID: 1207452
    [No Abstract]   [Full Text] [Related]  

  • 63. [Disorders in the conversion of fibrinogen to fibrin in patients with multiple myeloma].
    Lopaciuk S; Snigurowicz J; Rostkowska J; Pniejnia-Olszyński W; Powiertowska-Rezmer M
    Acta Haematol Pol; 1978; 9(3):157-64. PubMed ID: 102100
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Reptilase time (RT).
    Karapetian H
    Methods Mol Biol; 2013; 992():273-7. PubMed ID: 23546720
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Cleavage of blood coagulation factor XIII and fibrinogen by thrombin during in vitro clotting.
    Greenberg CS; Miraglia CC; Rickles FR; Shuman MA
    J Clin Invest; 1985 May; 75(5):1463-70. PubMed ID: 2860124
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Fibrin formation and proteolysis during ancrod treatment. Evidence for des-A-profibrin formation and thrombin independent factor XIII activity.
    Dempfle CE; Argiriou S; Alesci S; Kucher K; Müller-Peltzer H; Rübsamen K; Heene DL
    Ann N Y Acad Sci; 2001; 936():210-4. PubMed ID: 11460476
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Thrombin activity of fibrin thrombi and soluble plasmic derivatives.
    Francis CW; Markham RE; Barlow GH; Florack TM; Dobrzynski DM; Marder VJ
    J Lab Clin Med; 1983 Aug; 102(2):220-30. PubMed ID: 6223106
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A study of fibrinogen and fibrinolysis in 10 adults with nephrotic syndrome.
    Gandrille S; Jouvin MH; Toulon P; Remy P; Fiessinger JN; Roncato M; Moatti N; Aiach M
    Thromb Haemost; 1988 Jun; 59(3):445-50. PubMed ID: 3142081
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Human factor XIa cleaves fibrinogen: effects on structure and function.
    Scott CF; Mentzer RL; Budzynski AZ; Colman RW
    Arch Biochem Biophys; 1986 Sep; 249(2):480-8. PubMed ID: 2944482
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A two-step fibrinogen--fibrin transition in blood coagulation.
    Blombäck B; Hessel B; Hogg D; Therkildsen L
    Nature; 1978 Oct; 275(5680):501-5. PubMed ID: 692730
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Relations between the concentration of fibrinogen, thromboplastin time, thrombin time and reptilase time in patients treated with Arwin].
    Paar D; Klüken N
    Med Welt; 1975 Sep; 26(38):1700-1. PubMed ID: 1186461
    [No Abstract]   [Full Text] [Related]  

  • 72. The isolation of fibrinogen monomer dramatically influences fibrin polymerization.
    Huang L; Lord ST
    Thromb Res; 2013 Jun; 131(6):e258-63. PubMed ID: 23622556
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Dysfibrinogenemia. A new case: dysfibrinogenemia Giessen III (author's transl)].
    Matthias FR; Krause WH; Ganssert S; Mueller K; Lasch HG
    Klin Wochenschr; 1977 Jun; 55(11):539-43. PubMed ID: 881774
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Fibrinogen Cleveland II. An abnormal fibrinogen with defective release of fibrinopeptide A.
    Crum ED; Shainoff JR; Graham RC; Ratnoff OD
    J Clin Invest; 1974 May; 53(5):1308-19. PubMed ID: 4856883
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Functional analysis for dysfibrinogenemias, Toyama and Adachi, which have a mutation of Aalpha16Arg-->His (CGT-->CAT) with aberrant fibrinopeptide A release].
    Soya K; Takezawa Y; Terasawa F; Okumura N
    Rinsho Byori; 2012 Jun; 60(6):499-505. PubMed ID: 22880226
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The role of sodium citrate in the dysfibrinogenaemia of liver disease.
    Francis JL; Watson NJ; Simmonds VJ
    Thromb Res; 1984 May; 34(3):187-97. PubMed ID: 6729777
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Inhibitor of the thrombin time in systemic amyloidosis: a common coagulation abnormality.
    Gastineau DA; Gertz MA; Daniels TM; Kyle RA; Bowie EJ
    Blood; 1991 Jun; 77(12):2637-40. PubMed ID: 1904284
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Intravascular coagulation in acute hepatic failure.
    Rake MO; Flute PT; Brodonova M; Escartin P; Williams R
    Clin Sci; 1970 Mar; 38(3):15P. PubMed ID: 5442537
    [No Abstract]   [Full Text] [Related]  

  • 79. The use of the platelet aggregometer to monitor thrombin-induced conversion of fibrinogen to fibrin.
    Ruda EM; Thompson NT; Scrutton MC
    Thromb Res; 1985 Dec; 40(5):703-9. PubMed ID: 4089835
    [No Abstract]   [Full Text] [Related]  

  • 80. Comparison of polymerization of ancrod and thrombin fibrin monomers.
    Spellman GG; Macoviak JA; Gralnick HR
    Blood; 1977 Oct; 50(4):619-24. PubMed ID: 20184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.